The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2024 Apr 27

PMID 38672269

Authors

Miruna-Maria Apetroaei

Bruno Stefan Velescu

Marina Ionela Ilie Nedea

Cristina Elena Dinu-Pirvu

Doina Draganescu

Anca Ionela Faca

Denisa Ioana Udeanu

Andreea Letitia Arsene

Affiliations

Soon will be listed here.

Abstract

Human immunodeficiency virus (HIV) is a significant global health issue that affects a substantial number of individuals across the globe, with a total of 39 million individuals living with HIV/AIDS. ART has resulted in a reduction in HIV-related mortality. Nevertheless, the issue of medication resistance is a significant obstacle in the management of HIV/AIDS. The unique genetic composition of HIV enables it to undergo rapid mutations and adapt, leading to the emergence of drug-resistant forms. The development of drug resistance can be attributed to various circumstances, including noncompliance with treatment regimens, insufficient dosage, interactions between drugs, viral mutations, preexposure prophylactics, and transmission from mother to child. It is therefore essential to comprehend the molecular components of HIV and the mechanisms of antiretroviral medications to devise efficacious treatment options for HIV/AIDS.

Citing Articles

Predictive value of neutrophil to lymphocyte ratio for the clinical outcomes of acquired immune deficiency syndrome: a systematic review and meta-analysis.

Guo F, Chen J, Zhang H Front Med (Lausanne). 2025; 12:1503614.

PMID: 39975671 PMC: 11835827. DOI: 10.3389/fmed.2025.1503614.

Drug-Drug Interactions in Nosocomial Infections: An Updated Review for Clinicians.

Hincu S, Apetroaei M, Stefan G, Faca A, Arsene A, Mahler B Pharmaceutics. 2024; 16(9).

PMID: 39339174 PMC: 11434876. DOI: 10.3390/pharmaceutics16091137.

An Overview of the Recent Advances in Antimicrobial Resistance.

Oliveira M, Antunes W, Mota S, Madureira-Carvalho A, Dinis-Oliveira R, Dias da Silva D Microorganisms. 2024; 12(9).

PMID: 39338594 PMC: 11434382. DOI: 10.3390/microorganisms12091920.

Ocular involvement in highly treatment-experienced patients with HIV.

Cobaschi M, Dorobat C, Dorobat V, Loghin I, Macovei M, Marinescu A Rom J Ophthalmol. 2024; 68(2):152-157.

PMID: 39006338 PMC: 11238857. DOI: 10.22336/rjo.2024.28.

References

Campbell E, Hope T . HIV-1 capsid: the multifaceted key player in HIV-1 infection. Nat Rev Microbiol. 2015; 13(8):471-83. PMC: 4876022. DOI: 10.1038/nrmicro3503. View

. Human Immunodeficiency Virus (HIV). Transfus Med Hemother. 2016; 43(3):203-22. PMC: 4924471. DOI: 10.1159/000445852. View

Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D . TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments. J Virol. 2005; 79(20):12773-82. PMC: 1235844. DOI: 10.1128/JVI.79.20.12773-12782.2005. View

Rawson J, Landman S, Reilly C, Mansky L . HIV-1 and HIV-2 exhibit similar mutation frequencies and spectra in the absence of G-to-A hypermutation. Retrovirology. 2015; 12:60. PMC: 4496919. DOI: 10.1186/s12977-015-0180-6. View

Irlbeck D, Amrine-Madsen H, Kitrinos K, LaBranche C, Demarest J . Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. AIDS. 2008; 22(12):1425-31. DOI: 10.1097/QAD.0b013e32830184ba. View

Rimsky L, Shugars D, Matthews T . Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol. 1998; 72(2):986-93. PMC: 124569. DOI: 10.1128/JVI.72.2.986-993.1998. View

Lazzarin A . Enfuvirtide: the first HIV fusion inhibitor. Expert Opin Pharmacother. 2005; 6(3):453-64. DOI: 10.1517/14656566.6.3.453. View

Engelman A, Cherepanov P . The structural biology of HIV-1: mechanistic and therapeutic insights. Nat Rev Microbiol. 2012; 10(4):279-90. PMC: 3588166. DOI: 10.1038/nrmicro2747. View

De Clercq E . The design of drugs for HIV and HCV. Nat Rev Drug Discov. 2007; 6(12):1001-18. DOI: 10.1038/nrd2424. View

10.

Fofana D, Charpentier C, Maiga A, Lambert-Niclot S, Sayon S, Desire N . Genetic barrier for attachment inhibitor BMS-626529 resistance in HIV-1 B and non-B subtypes. J Antimicrob Chemother. 2014; 70(1):130-5. DOI: 10.1093/jac/dku360. View

11.

Edwards G, Miyashita-Ochoa A, Castillo E, Goodman-Meza D, Kalofonos I, Landovitz R . Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine. AIDS Behav. 2022; 27(1):10-24. PMC: 9443641. DOI: 10.1007/s10461-022-03817-z. View

12.

van Welzen B, Van Lelyveld S, Ter Beest G, Gisolf J, Geerlings S, Prins J . Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis. Clin Infect Dis. 2024; 79(1):189-195. PMC: 11259215. DOI: 10.1093/cid/ciae016. View

13.

Wohl D, Cohen C, Gallant J, Mills A, Sax P, DeJesus E . A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr. 2013; 65(3):e118-20. DOI: 10.1097/QAI.0000000000000057. View

14.

Hiryak K, Koren D . Fostemsavir: A Novel Attachment Inhibitor for Patients With Multidrug-Resistant HIV-1 Infection. Ann Pharmacother. 2020; 55(6):792-797. DOI: 10.1177/1060028020962424. View

15.

Zdanowicz M . The pharmacology of HIV drug resistance. Am J Pharm Educ. 2006; 70(5):100. PMC: 1637011. DOI: 10.5688/aj7005100. View

16.

Li G, Piampongsant S, Faria N, Voet A, Pineda-Pena A, Khouri R . An integrated map of HIV genome-wide variation from a population perspective. Retrovirology. 2015; 12:18. PMC: 4358901. DOI: 10.1186/s12977-015-0148-6. View

17.

Frentz D, Vijver D, Abecasis A, Albert J, Hamouda O, Jorgensen L . Patterns of transmitted HIV drug resistance in Europe vary by risk group. PLoS One. 2014; 9(4):e94495. PMC: 3983178. DOI: 10.1371/journal.pone.0094495. View

18.

Kirby T, Thornber-Dunwell M . Uptake of PrEP for HIV slow among MSM. Lancet. 2014; 383(9915):399-400. DOI: 10.1016/s0140-6736(14)60137-9. View

19.

Roche M, Salimi H, Duncan R, Wilkinson B, Chikere K, Moore M . A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations. Retrovirology. 2013; 10:43. PMC: 3648390. DOI: 10.1186/1742-4690-10-43. View

20.

Thoueille P, Choong E, Cavassini M, Buclin T, Decosterd L . Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother. 2021; 77(2):290-302. PMC: 8809192. DOI: 10.1093/jac/dkab324. View